Position in ABBV
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$201,060
+$132,109 QoQ
Shares Held
799
+98.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#3,958
of 4,153 holders
Holding Since
Jun 2021
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Castleview Partners, LLC holds $12,261,738 across 7 Drug Manufacturers - General names. ABBV ranks #7 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
83,526 | $4,812,768 | |
| 2 | AMGN |
Amgen Inc
|
10,552 | $3,821,090 | |
| 3 | LLY |
ELI LILLY & Co
|
909 | $1,090,281 | |
| 4 | JNJ |
Johnson & Johnson
|
4,044 | $1,027,054 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
6,286 | $794,173 | |
| 6 | PFE |
Pfizer Inc
|
21,400 | $515,312 | |
| 7 | ABBV |
AbbVie Inc.
This page
|
799 | $201,060 |
All Filings in ABBV
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $201,060 | 799 | Shares | Sole | 2026-07-20 | |
| 2024-06-30 | $68,951 | 402 | Shares | Sole | 2024-07-31 | |
| 2024-03-31 | $88,136 | 484 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $74,695 | 482 | Shares | Sole | 2024-02-05 | |
| 2023-09-30 | $41,736 | 280 | Shares | Sole | 2023-10-26 | |
| 2023-06-30 | $46,616 | 346 | Shares | Sole | 2023-08-15 | |
| 2023-03-31 | $51,795 | 325 | Shares | Sole | 2023-05-16 | |
| 2022-12-31 | $52,200 | 323 | Shares | Sole | 2023-02-01 | |
| 2022-09-30 | $17,178 | 128 | Shares | Sole | 2022-11-10 | |
| 2022-03-31 | $308,009 | 1,900 | Shares | Sole | 2022-05-16 | |
| 2021-12-31 | $9,086,000 | 1,230,338 | Shares | Sole | 2022-02-17 | |
| 2021-06-30 | $1,139,578 | 10,117 | Shares | Sole | 2021-08-17 | |
| No filing history on record for this holder in this stock. | ||||||